[글로벌-이슈 24] AstraZeneca “Identifying the impact of Corona 19 strains… aiming to exert efficacy on vaccine strains”

British pharmaceutical company AstraZeneca on the 22nd (local time) emphasized that the new coronavirus infection (Corona 19) vaccine should be effective against the virus strain.

In addition, AstraZeneca said it is conducting research to fully understand the effects of the mutation.

AstraZeneca said it was preparing for the Corona 19 variant by e-mailing to Reuters’ inquiries that day. According to Reuters, AstraZeneca said in an email response, “AZD1222 (AstraZeneca’s COVID-19 betrayal candidate) contains the SARS (Severe Acute Respiratory Syndrome) spike protein genetic material. It is not detected in structural changes.”

AstraZeneca’s COVID-19 vaccine was created by removing the toxicity of the adenovirus, which causes cold in chimpanzees, and then inserting the gene for the spike protein of SARS coronavirus-2.

When immune cells detect the spike protein, they use adenovirus as a carrier (vector) to produce antibodies. It is collectively referred to as’adenovirus vector vaccine’ and its official name is AZD1222.

AstraZeneca added, “With the AZD1222 vaccination, we are training the body’s immune system to recognize various parts of the spike protein. This training allows us to get rid of the virus if exposed later.”

Pharmaceutical companies such as AstraZeneca are strengthening their corona 19 vaccine trials to combat the rapidly spreading virus strain in the UK and other places.

Global Economic Reporter Myung-Hyun Myung-Hyun [email protected]